ClinicalTrials.gg
RecruitingNCT07854652Updated Nov 16, 2026

BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia

A Phase 1 interventional study of Ifupinostat Hydrochloride in B-cell Precursor Acute Lymphoblastic Leukemia (ALL), sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 14 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 1, Interventional, and Treatment

How we know

Updated Nov 16, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
14 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by The First Affiliated Hospital of Soochow University — 10 open to participants now, 12 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · The First Affiliated Hospital of Soochow University.

Planned enrollment
14th of 14
15 · median 34
Started
2026
with 2 others
Phase 1
3 of 14
3 open now
Primary completion
2028-08
later than 9 of 11 live
Registered
14th of 14
by date

Among the 14 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by The First Affiliated Hospital of Soochow University, this one is the 14th largest by planned enrollment, is one of 3 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 9 of the 11 other live ones, and was the 14th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

10 of the 14 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by The First Affiliated Hospital of Soochow University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 14 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by The First Affiliated Hospital of Soochow University, or all of them as a file.
02

Study summary

This is a single-center, open-label, exploratory study evaluating ifupinostat hydrochloride (BEBT-908) in patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with MEF2D rearrangement. The study will include patients with relapsed or refractory disease and patients who are in morphologic remission but still have measurable residual disease (MRD).

The main purpose of the study is to evaluate the preliminary anti-leukemia activity of BEBT-908 in patients with relapsed or refractory disease and its ability to reduce or eliminate residual leukemia in patients with MRD-positive disease. The study will also assess the depth and duration of response, survival outcomes, subsequent treatment such as stem cell transplantation or CAR-T therapy, and the safety and tolerability of BEBT-908.

Approximately 10 to 15 participants aged 14 to 75 years are planned to be enrolled. All participants will receive BEBT-908 by intravenous infusion at 18.5 mg/m² on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle for up to two cycles. Bone marrow morphology, flow cytometry MRD, and MEF2D fusion transcript levels will be evaluated during the study to assess treatment response.

03

Conditions studied

  • B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
04

Who can participate

Ages eligible
14 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the study and provision of written . For participants aged 14-17 years, written informed consent must be provided by a legal guardian, together with the participant's assent or confirmation as required by the ethics committee.
  2. Age ≥14 years and ≤75 years at the time of informed consent, regardless of sex.
  3. Diagnosis of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) based on morphology, immunophenotyping, and clinical assessment.
  4. Prior clinical testing suggesting MEF2D rearrangement, with confirmation of the MEF2D rearrangement and its specific fusion partner during screening by RNA sequencing or a targeted RNA fusion panel.
  5. Meets either of the following baseline disease-status criteria:

    1. disease: relapse, refractory disease, or disease progression after at least one line of systemic anti-leukemia therapy, with evaluable bone marrow and ≥5% blasts/lymphoblasts at screening; or
    2. Morphologic remission with MRD positivity: achievement of CR, CRh, or CRi after at least one course of standard induction or salvage therapy, with flow cytometry MRD ≥0.01% and/or MEF2D fusion transcript/ABL1 ≥0.1% at screening.
  6. Bone marrow morphology, flow cytometry MRD, and quantitative RT-qPCR for the MEF2D fusion transcript are all performed during screening and meet the applicable baseline stratification and enrollment requirements. Participants in MLFS are not eligible through the MRD-positive pathway.
  7. (ECOG) performance status of 0-2.
  8. Estimated >12 weeks.
  9. Peripheral blood white blood cell count \<25 × 10\^9/L before the first dose of ifupinostat hydrochloride; cytoreduction during screening is permitted to achieve this threshold.
  10. Adequate organ function:

    • and AST ≤2.5 × ; values up to ≤5 × ULN may be permitted when abnormalities are attributable to leukemic hepatic involvement, prior therapy, or another controllable cause, at the investigator's discretion;
    • Total ≤1.5 × ULN; ≤3 × ULN is permitted for Gilbert syndrome;
    • ≥50 mL/min;
    • (LVEF) ≥45%.
  11. No active central nervous system leukemia on cerebrospinal fluid examination during screening.
  12. Prior therapy meets the protocol-specified washout requirements, and acute non-hematologic toxicities have recovered to Grade 0-1, baseline, or a clinically stable level. Reductions in ANC, , or count attributable to leukemia or prior therapy are not exclusionary.
  13. Participants of agree to use effective during study treatment and for the protocol-specified period after the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Isolated extramedullary relapse, or active extramedullary leukemia without bone marrow disease meeting one of the protocol-defined enrollment pathways.
  2. Active central nervous system leukemia.
  3. Failure to confirm MEF2D rearrangement during screening.
  4. White blood cell count ≥25 × 10\^9/L before the first dose despite cytoreduction, or an unacceptable risk of leukostasis, tumor lysis syndrome, severe infection, severe bleeding, or other acute complications as judged by the investigator.
  5. Inadequate washout from prior therapy:

    • Chemotherapy, radiotherapy, immunotherapy, or other clearly anti-leukemia treatment within 14 days;
    • Small-molecule or targeted therapy within 14 days or 5 half-lives, whichever is shorter;
    • Large-molecule therapy within 28 days or 5 half-lives, whichever is shorter;
    • CAR-T therapy or transplantation within 60 days with ongoing active CRS, ICANS, or uncontrolled toxicity;
    • Allogeneic transplantation within 100 days, or active or ongoing systemic therapy.
  6. Uncontrolled active infection, active invasive fungal infection, active tuberculosis, sepsis, or septic shock.
  7. Uncontrolled , , or infection; active syphilis; or active EBV- or CMV-related organ disease.
  8. Screening >450 ms in males or >470 ms in females; congenital long QT syndrome; arrhythmia; or requirement for continued use of an irreplaceable medication known to prolong the QT interval.
  9. Uncontrolled or clinically significant cardiovascular disease, including recent myocardial infarction, unstable angina, severe heart failure, or severe arrhythmia.
  10. Pregnancy or breastfeeding.
  11. Known to ifupinostat or any component of the formulation.
  12. Inability to avoid strong inducers, or requirement for long-term use of strong CYP3A4 inhibitors or QT-prolonging drugs that cannot be safely managed.
  13. Another that may interfere with assessment of efficacy or safety in this study, except for malignancies considered cured and at low risk of recurrence at the investigator's discretion.
  14. Psychiatric, cognitive, or compliance-related problems that prevent adequate understanding of or adherence to study requirements.
  15. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    BEBT-908 Monotherapy

    Drug: Ifupinostat Hydrochloride

Interventions

  • DrugBEBT-908Studies of BEBT-908BEBT-908 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ifupinostat hydrochloride (BEBT-908) will be administered intravenously at a dose of 18.5 mg/m² on Days 1, 3, 5, 8, 10, and 12 of each 21-day cycle for up to 2 cycles. Each dose will be administered as a constant-rate intravenous infusion over 30 ± 5 minutes.

    Also known as: BEBT-908

06

What researchers measure

Primary outcomes

  1. Overall Response Rate in Participants With Relapsed/Refractory Disease

    The proportion of participants with relapsed/refractory MEF2D-rearranged BCP-ALL who achieve a best overall response of complete remission (CR), CR with partial hematologic recovery (CRh), CR with incomplete hematologic recovery (CRi), or morphologic leukemia-free state (MLFS) during the first 2 treatment cycles.

    Time frame: From first dose through Cycle 2 Day 21 ± 3 days (approximately 6 weeks)

  2. Complete MRD Response Rate in Participants With MRD-Positive Disease

    The proportion of participants with morphologic remission but MRD-positive MEF2D-rearranged BCP-ALL who achieve a complete MRD response, defined as flow cytometry MRD \<0.01% and MEF2D fusion transcript/ABL1 \<0.1% at the same assessment time point, with both measurements evaluable.

    Time frame: From first dose through Cycle 2 Day 21 ± 3 days

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time from the first dose of ifupinostat hydrochloride to death from any cause. Participants who remain alive will be censored at the date they were last known to be alive.

    Time frame: From first dose until death or last known follow-up, up to approximately 30 months

  2. Event-Free Survival

    Event-free survival (EFS) will be evaluated separately by baseline disease stratum. In the relapsed/refractory stratum, events include failure to achieve CR, CRh, CRi, or MLFS after 2 cycles, disease progression, morphologic relapse after response, initiation of new anti-leukemia therapy for insufficient efficacy, or death from any cause. In the MRD-positive stratum, events include failure to achieve complete MRD response after 2 cycles, MRD progression, morphologic relapse, initiation of new anti-leukemia therapy for insufficient efficacy, or death from any cause.

    Time frame: From first dose until an EFS event or last follow-up, up to approximately 30 months

  3. Incidence of Adverse Events and Serious Adverse Events

    Incidence and severity of adverse events (AEs), serious adverse events (SAEs), Grade 3-4 AEs, and treatment-related AEs, assessed using NCI CTCAE version 5.0. Events will also be summarized by relationship to study treatment and by whether they resulted in treatment interruption, modification, or discontinuation.

    Time frame: From first dose through 28 days after the last dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Aug 2028, 20 months later.

Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 20 months is below that.

Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Dec 1, 2026was Sep 2026
Primary completionEst.
Aug 30, 2028
CompletionEst.
Aug 30, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Dec 1, 2026
Nov 16, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 16, 2026
    Start date Sep 1, 2026→Dec 1, 2026
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854652
Collaborators
Guangzhou BeBetter Med Co., Ltd
Responsible party
Chen Suning (Professor, Chief Physician, and Doctoral Supervisor, The First Affiliated Hospital of Soochow University) — Principal investigator
First posted
Oct 2, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 30, 2028 (estimated)
Completion
Aug 30, 2030 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BEBT-908

Start the discussion